Sweeneys to make room for new leadership at Dorland

Share this article:
L-r: Rich Minoff will become president/CEO of Dorland Global, succeeding Rita and Harry Sweeney
L-r: Rich Minoff will become president/CEO of Dorland Global, succeeding Rita and Harry Sweeney
Harry and Rita Sweeney, the couple who founded medical communications firm Dorland Global 35 years ago, will leave their executive positions as of January 1st, 2008, the agency announced yesterday. Assuming the role of CEO and president will be Rich Minoff, a five-year veteran who helped orchestrate the $20.7-million sale of Dorland to Huntsworth PLC earlier this year.
The 125-person agency maintains two business units, advertising and PR. Clients include Johnson & Johnson, Roche and Boston Scientific.
“Harry and I are confident that [Minoff] will not only continue to service our clients and employees in the manner that Dorland Global is known for, but will also take the agency in a new direction with the Huntsworth organization,” said Rita Sweeney, who had served as president, chief operating officer. The COO position will be eliminated. Her husband is stepping down as CEO.
Minoff joined the agency in 2002 as president of Dorland Global Health Communications, a branding and marketing division which has grown 47% per year under his watch. In addition, he has 14 years of senior managerial experience at various agencies, along with 12 years on the client side working for GlaxoSmithKline and Wyeth.
Thanks to the March purchase, Dorland Global's two main business units, Dorland Global Health Communications and Dorland Global Public Relations, now serve as the US affiliate of the UK-based Huntsworth health division.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.